Adaptive Biotechnologies Showcases clonoSEQ Test at ASCO and EHA Meetings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Newsfilter
- Clinical Presentation Volume: Adaptive Biotechnologies will showcase its clonoSEQ® test in 33 presentations at ASCO and EHA, including one plenary session and 14 oral presentations, highlighting the test's significance and broad application in modern hematologic oncology.
- Multiple Myeloma Research: The clonoSEQ test demonstrates depth and durability of response to novel therapies in the inMMyCAR trial and MONUMENTAL-3 study, with final analysis showing higher rates of sustained MRD negativity in patients treated with the quadruplet regimen, thereby enhancing evidence-based treatment decisions.
- Chronic Lymphocytic Leukemia Applications: In studies like BOVen-∆MRD400 and venetoSTOP, MRD measurement is incorporated into therapy duration and discontinuation decisions, indicating that personalized treatment can lead to durable treatment-free remissions, significantly improving patient quality of life.
- Global Impact Expansion: New data presented at EHA further supports the application of clonoSEQ in MRD assessment, with increasing biopharmaceutical industry investment in MRD-guided treatment driving significant growth in clonoSEQ's global influence and market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.190
Low
20.00
Averages
20.86
High
22.00
Current: 15.190
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adaptive Biotechnologies Showcases clonoSEQ Test at ASCO and EHA Meetings
- Clinical Presentation Volume: Adaptive Biotechnologies will showcase its clonoSEQ® test in 33 presentations at ASCO and EHA, including one plenary session and 14 oral presentations, highlighting the test's significance and broad application in modern hematologic oncology.
- Multiple Myeloma Research: The clonoSEQ test demonstrates depth and durability of response to novel therapies in the inMMyCAR trial and MONUMENTAL-3 study, with final analysis showing higher rates of sustained MRD negativity in patients treated with the quadruplet regimen, thereby enhancing evidence-based treatment decisions.
- Chronic Lymphocytic Leukemia Applications: In studies like BOVen-∆MRD400 and venetoSTOP, MRD measurement is incorporated into therapy duration and discontinuation decisions, indicating that personalized treatment can lead to durable treatment-free remissions, significantly improving patient quality of life.
- Global Impact Expansion: New data presented at EHA further supports the application of clonoSEQ in MRD assessment, with increasing biopharmaceutical industry investment in MRD-guided treatment driving significant growth in clonoSEQ's global influence and market demand.
See More
Harvest Investment Fully Exits Adaptive Biotechnologies Stake
- Complete Exit: Harvest Investment Services sold its entire stake of 356,114 shares in Adaptive Biotechnologies during Q1 2026, valued at approximately $5.67 million, indicating a potential loss of confidence that may impact market perception of Adaptive.
- Asset Reallocation: Following this transaction, Adaptive Biotechnologies now represents 0% of Harvest's 13F reportable assets, with its top five holdings including NASDAQ: LMBS at 8.16%, reflecting a strategic shift in Harvest's investment focus.
- Market Performance Comparison: As of May 26, 2026, Adaptive Biotechnologies shares were priced at $114.09, up 57.78% year-over-year, outperforming the S&P 500 by 28.3 percentage points, highlighting its strong position in the biotechnology sector.
- Future Growth Potential: Although Harvest's exit may be a short-term decision, Adaptive's MRD testing sales surged by 53% year-over-year, indicating significant growth potential in cancer diagnostics that could attract renewed investor interest.
See More
Adaptive Biotechnologies Reports Strong Q1 2026 Earnings with Revenue Growth
- MRD Revenue Growth: Adaptive Biotechnologies reported a 53% year-over-year increase in MRD revenue for Q1 2026, reaching $67.1 million, indicating strong performance in precision medicine and likely enhancing future market share.
- Margin Improvement: The company's sequencing gross margin rose to 70% this quarter, an 8 percentage point increase from the previous year, reflecting improved cost control and operational efficiency, which is expected to bolster investor confidence.
- Strong Cash Position: At the end of the quarter, the company had approximately $222 million in cash reserves, ensuring financial flexibility for future R&D and market expansion, supporting its long-term growth strategy.
- Upward Revenue Guidance: The company raised its full-year MRD revenue guidance to a range of $260 million to $270 million, reflecting management's optimistic outlook on market demand while emphasizing ongoing cost control efforts.
See More
Adaptive Biotechnologies Executive Stock Transaction Overview
- Transaction Overview: On April 27, 2026, Adaptive Biotechnologies' COO Julie Rubinstein exercised 14,707 options and sold 19,037 shares of common stock for approximately $271,000, while retaining 377,802 shares valued at about $5.37 million, indicating continued confidence in the company.
- Ownership Change: The 19,037 shares sold represented 4.8% of Rubinstein's direct common stock holdings, reflecting a modest reduction in her equity exposure, yet she maintains a significant economic interest in the firm.
- Planned Trading Context: Rubinstein's transaction was executed under a Rule 10b5-1 trading plan established in November 2025, which is typically used by executives to mitigate insider trading allegations, suggesting her actions were strategic rather than impulsive.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, despite an operating loss of $57.1 million, which is a significant improvement from the previous year's loss of $162.5 million, indicating potential for cost control and sales growth moving forward.
See More
Adaptive Biotechnologies COO Executes Stock Sale
- Executive Stock Sale: COO Julie Rubinstein sold 19,037 shares on April 27, 2026, at an average price of approximately $14.23 per share, totaling around $271,000, which reduced her direct holdings by 4.8%, indicating continued executive engagement with the company's stock.
- Options Exercise Details: The transaction involved the exercise of 14,707 options executed directly without indirect participation, demonstrating Rubinstein's adherence to a Rule 10b5-1 trading plan, thereby mitigating insider trading concerns.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, although it faced an operating loss of $57.1 million, significantly down from a $162.5 million loss in 2024, indicating improved cost management.
- Market Outlook Analysis: Despite the stock price retreating from its 52-week high of $20.76, investors should monitor the company's potential for future sales growth, especially as operating costs are expected to rise modestly, suggesting a possible buying opportunity at current levels.
See More
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
Adaptive Biotechnologies Showcases clonoSEQ Test at ASCO and EHA Meetings
- Clinical Presentation Volume: Adaptive Biotechnologies will showcase its clonoSEQ® test in 33 presentations at ASCO and EHA, including one plenary session and 14 oral presentations, highlighting the test's significance and broad application in modern hematologic oncology.
- Multiple Myeloma Research: The clonoSEQ test demonstrates depth and durability of response to novel therapies in the inMMyCAR trial and MONUMENTAL-3 study, with final analysis showing higher rates of sustained MRD negativity in patients treated with the quadruplet regimen, thereby enhancing evidence-based treatment decisions.
- Chronic Lymphocytic Leukemia Applications: In studies like BOVen-∆MRD400 and venetoSTOP, MRD measurement is incorporated into therapy duration and discontinuation decisions, indicating that personalized treatment can lead to durable treatment-free remissions, significantly improving patient quality of life.
- Global Impact Expansion: New data presented at EHA further supports the application of clonoSEQ in MRD assessment, with increasing biopharmaceutical industry investment in MRD-guided treatment driving significant growth in clonoSEQ's global influence and market demand.
See More
Harvest Investment Fully Exits Adaptive Biotechnologies Stake
- Complete Exit: Harvest Investment Services sold its entire stake of 356,114 shares in Adaptive Biotechnologies during Q1 2026, valued at approximately $5.67 million, indicating a potential loss of confidence that may impact market perception of Adaptive.
- Asset Reallocation: Following this transaction, Adaptive Biotechnologies now represents 0% of Harvest's 13F reportable assets, with its top five holdings including NASDAQ: LMBS at 8.16%, reflecting a strategic shift in Harvest's investment focus.
- Market Performance Comparison: As of May 26, 2026, Adaptive Biotechnologies shares were priced at $114.09, up 57.78% year-over-year, outperforming the S&P 500 by 28.3 percentage points, highlighting its strong position in the biotechnology sector.
- Future Growth Potential: Although Harvest's exit may be a short-term decision, Adaptive's MRD testing sales surged by 53% year-over-year, indicating significant growth potential in cancer diagnostics that could attract renewed investor interest.
See More
Adaptive Biotechnologies Reports Strong Q1 2026 Earnings with Revenue Growth
- MRD Revenue Growth: Adaptive Biotechnologies reported a 53% year-over-year increase in MRD revenue for Q1 2026, reaching $67.1 million, indicating strong performance in precision medicine and likely enhancing future market share.
- Margin Improvement: The company's sequencing gross margin rose to 70% this quarter, an 8 percentage point increase from the previous year, reflecting improved cost control and operational efficiency, which is expected to bolster investor confidence.
- Strong Cash Position: At the end of the quarter, the company had approximately $222 million in cash reserves, ensuring financial flexibility for future R&D and market expansion, supporting its long-term growth strategy.
- Upward Revenue Guidance: The company raised its full-year MRD revenue guidance to a range of $260 million to $270 million, reflecting management's optimistic outlook on market demand while emphasizing ongoing cost control efforts.
See More
Adaptive Biotechnologies Executive Stock Transaction Overview
- Transaction Overview: On April 27, 2026, Adaptive Biotechnologies' COO Julie Rubinstein exercised 14,707 options and sold 19,037 shares of common stock for approximately $271,000, while retaining 377,802 shares valued at about $5.37 million, indicating continued confidence in the company.
- Ownership Change: The 19,037 shares sold represented 4.8% of Rubinstein's direct common stock holdings, reflecting a modest reduction in her equity exposure, yet she maintains a significant economic interest in the firm.
- Planned Trading Context: Rubinstein's transaction was executed under a Rule 10b5-1 trading plan established in November 2025, which is typically used by executives to mitigate insider trading allegations, suggesting her actions were strategic rather than impulsive.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, despite an operating loss of $57.1 million, which is a significant improvement from the previous year's loss of $162.5 million, indicating potential for cost control and sales growth moving forward.
See More
Adaptive Biotechnologies COO Executes Stock Sale
- Executive Stock Sale: COO Julie Rubinstein sold 19,037 shares on April 27, 2026, at an average price of approximately $14.23 per share, totaling around $271,000, which reduced her direct holdings by 4.8%, indicating continued executive engagement with the company's stock.
- Options Exercise Details: The transaction involved the exercise of 14,707 options executed directly without indirect participation, demonstrating Rubinstein's adherence to a Rule 10b5-1 trading plan, thereby mitigating insider trading concerns.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, although it faced an operating loss of $57.1 million, significantly down from a $162.5 million loss in 2024, indicating improved cost management.
- Market Outlook Analysis: Despite the stock price retreating from its 52-week high of $20.76, investors should monitor the company's potential for future sales growth, especially as operating costs are expected to rise modestly, suggesting a possible buying opportunity at current levels.
See More
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
